The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb

Journal of Children's Orthopaedics

Volumn 4, Issue 3, 2010, Pages 183-195

  Molenaers, Guy ^a,b   van Campenhout, Anja ^a,b   Fagard, Katrien ^a   de Cat, Jos ^a   Desloovere, Kaat ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Botulinum toxin A; Cerebral palsy; Lower limb; Multi level treatment

Indexed keywords

EID: 77952386268     PISSN: 18632521     EISSN: 18632548     Source Type: Journal    
DOI: 10.1007/s11832-010-0246-x     Document Type: Review

References (89)

1. Rang M (1993) In: Wenger DR, Rang M (eds) Cerebral palsy in the art and practice of children's orthopaedics. Raven Press, New York.
2. Himmelmann K, Hagberg G, Beckung E, Hagberg B, Uvebrant P (2005) The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatr 94: 287-294.
3. McManus V, Guillem P, Surman G, Cans C (2006) SCPE work, standardization and definition-an overview of the activities of SCPE: a collaboration of European CP registers. Zhongguo Dang Dai Er Ke Za Zhi 8(4): 261-265.
4. Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8: 21-29.
5. Aoki KR (2002) Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Brin MF, Hallett M, Jankovic J (eds) Scientific and therapeutic aspects of botulinum toxin. Lippincott Williams & Wilkins, Philadelphia, pp 103-113.
6. Jankovic J (2004) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75: 951-957.
7. Aoki KR, Ranoux D, Wissel J (2006) Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 13: 10-19.
8. Lukban MB, Rosales RL, Dressler D (2009) Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm 116(3): 319-331.
9. Aoki KR (2003) Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 21: 476-480.
10. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96(6): 3200-3205.
11. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, Andersen GL, Aydin R, Becher JG, Bernert G, Caballero IM, Carr L, Valayer EC, Desiato MT, Fairhurst C, Filipetti P, Hassink RI, Hustedt U, Jozwiak M, Kocer SI, Kolanowski E, Krägeloh-Mann I, Kutlay S, Mäenpää H, Mall V, McArthur P, Morel E, Papavassiliou A, Pascual-Pascual I, Pedersen SA, Plasschaert FS, van der Ploeg I, Remy-Neris O, Renders A, Di Rosa G, Steinlin M, Tedroff K, Valls JV, Viehweger E, Molenaers G (2010) The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 1: 45-66.
12. Molenaers G, Desloovere K, Eyssen M, Decat J, Jonkers I, De Cock P (1999) Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol 6: S51-S57.
13. Kinnett D (2004) Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 83: S59-S64.
14. Gage JR (1991) Gait analysis in cerebral palsy. Mac Keith Press, London, pp 101-131.
15. Fabry G, Liu XC, Molenaers G (1999) Gait pattern in patients with spastic diplegic cerebral palsy who underwent staged operations. J Pediatr Orthop B 8: 33-38.
16. Wenger DR, Rang M (1993) The art and practice of children's orthopaedics. Raven Press, New York.
17. Gage JR, DeLuca PA, Renshaw TS (1995) Gait analysis: principles and applications. J Bone Joint Surg Am 77: 1607-1623.
18. DeLuca PA, Davis RB 3rd, Ounpuu S, Rose S, Sirkin R (1997) Alterations in surgical decision making in patients with cerebral palsy based on three-dimensional gait analysis. J Pediatr Orthop 17: 608-614.
19. Molenaers G, Desloovere K, Fabry G, De Cock P (2006) The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 88: 161-170.
20. Gómez Pellico L, Rodríguez Torres R, Dankloff Mora C (1995) Changes in walking pattern between five and six years of age. Dev Med Child Neurol 37: 800-806.
21. Desloovere K, Molenaers G, Eyssen M (1998) The three dimensional kinematics, kinetics and EMG pattern of the walking gait cycle of children aged between three and six years. Gait Posture 8: 76.
22. Zurcher AW, Molenaers G, Fabry G (1999) Treatment of equinus in young children with hemiplegic cerebral palsy: recurrence after Achilles tendon lengthening and kinematic and kinetic evaluation of treatment with botulinum toxin. Gait Posture 10: 90.
23. Borton DC, Walker K, Pirpiris M, Nattrass GR, Graham HK (2001) Isolated calf lengthening in cerebral palsy. Outcome analysis of risk factors. J Bone Joint Surg Br 83: 364-370.
24. Delp SL, Arnold AS, Piazza SJ (1998) Graphics-based modeling and analysis of gait abnormalities. Biomed Mater Eng 8: 227-240.
25. Desloovere K, Molenaers G, De Cat J, Pauwels P, van Campenhout A, Ortibus E, Fabry G, De Cock P (2007) Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Dev Med Child Neurol 49: 56-61.
26. Desloovere K, De Cat J, Schörkhuber V, van den Broeck C, Persyn A, Huenaerts C, Callewaert B, Molenaers G (2007) The effect of individually defined physiotherapy program based on gait analysis after BTX-A treatment in children with CP. Gait Posture 26: S26-S27.
27. Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, Matthews D, Molenaers G, Motta F, García Ruiz PJ, Wissel J (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11: 67-79.
28. Scott AB, Rosenbaum A, Collins CC (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 12: 924-927.
29. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28(4): 512-515.
30. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T (1993) Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop 13: 489-495.
31. Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T (1994) Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 14: 229-303.
32. Koman LA, Mooney JF 3rd, Smith BP, Walker F, Leon JM (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 20: 108-115.
33. Boyd RN, Pliatsios V, Starr R, Wolfe R, Graham HK (2000) Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 42: 32-41.
34. Cosgrove AP, Graham HK (1994) Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 36: 379-385.
35. Sławek J, Klimont L (2003) Functional improvement in cerebral palsy patients treated with botulinum toxin A injections-preliminary results. Eur J Neurol 10: 313-317.
36. Bakheit AMO, Severa S, Cosgrove A, Morton R, Roussounis SH, Doderlein L, Lin JP (2001) Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43(4): 234-238.
37. Galli M, Crivellini M, Santambrogio GC, Fazzi E, Motta F (2001) Short-term effects of 'botulinum toxin A' as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint. Funct Neurol 16: 317-323.
38. Mall V, Berweck S, Kirschner J, Herrmann J, Schelle A, Linder M, Michaelis U, Stein S, Korinthenberg R, Heinen F (2001) Die Therapie Spastischer Bewegungsstörungen im Kindesalter mit Botulinumtoxin A. Klin Neurophysiol 2001: 218-224.
39. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, Becher JG (2006) The combined effect of lower-limb multilevel botulinum toxin type A and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil 87: 1551-1558.
40. Desloovere K, Molenaers G, Feys H, Huenaerts C, Callewaert B, van de Walle P (2006) Do dynamic and static clinical measurements correlate with gait analysis parameters in children with cerebral palsy? Gait Posture 24: 302-313.
41. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, Eyssen M, Pauwels P, De Cock P (2001) A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 8: 75-87.
42. Awaad Y, Tayem H, Elgamal A, Coyne MF (1999) Treatment of childhood myoclonus with botulinum toxin type A. J Child Neurol 14: 781-786.
43. Awaad Y, Tayem H, Munoz S, Thomas R, Soliman S, Michon A, Minarik S (2000) High dose of botulinum toxin type-A (BTX/A): safety and efficacy in patients with cerebral palsy. J Pediatr Neurol 2: 91-96.
44. Aoki KR, Ismail M, Tang-Lui D, Brar B, Wheeler LA (1997) Botulinum toxin type A: from toxin to therapeutic agent. Eur J Neurol 4: S1-S3.
45. Goldstein EM (2006) Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 21: 189-192.
46. Flett PJ (2003) Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health 39: 6-14.
47. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20: 981-990.
48. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT (2001) Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108: 1062-1071.
49. Willis AW, Crowner B, Brunstrom JE, Kissel A, Racette BA (2007) High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 49: 818-822.
50. Adair B, Graham K (2009) Systemic adverse events following injection of botulinum toxin A (BoNT-A) in children with cerebral palsy. Dev Med Child Neurol 51(2): 54-55.
51. Sanders I, Shaari C, Amirali LAY (1999) The glycogen depletion assay and the measurement of botulinum toxin injections. Abstract from International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Orlando, Florida, November 16-18 1999, p 33.
52. Chell J, Hunter JB (2001) Urinary incontinence following botulinum toxin A injection in cerebral palsy. Abstract of the 20th EPOS Meeting, Montpellier, France, April 4-7 2001.
53. Francisco GE, Boake C, Vaughn A (2002) Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 81: 355-363.
54. Lee LR, Chuang YC, Yang BJ, Hsu MJ, Liu YH (2004) Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. Am J Phys Med Rehabil 83: 766-773.
55. Kawamura A, Campbell K, Lam-Damji S, Fehlings D (2007) A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 49: 331-337.
56. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM (2009) Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil 90: 9-16.
57. Molenaers G, Schörkhuber V, Fagard K, van Campenhout A, De Cat J, Pauwels P, Ortibus E, De Cock P, Desloovere K (2009) Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol 13(5): 421-429.
58. Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, Linder M, Kirschner J, Berweck S, Korinthenberg R, Heinen F, Fietzek UM (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55: 732-735.
59. ®) for cervical dystonia. Adv Ther 22: 49-55.
60. Alhusaini AA, Crosbie J, Shepherd R, Dean C (2009) Do botulinum toxin injections (BTX) alter the passive mechanical properties of the calf muscles in children with cerebral palsy (CP)? Dev Med Child Neurol 51(2): 54.
61. Desloovere K (2008) Efficacy of botulinum toxin A treatment in children with cerebral palsy is defined by crucial factors within the treatment strategy. Gait Posture 28: S1-S2.
62. Boyd R, Graham HK (1997) Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 4: S15-S22.
63. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 18: 304-311.
64. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35: 71-77.
65. Molenaers G, Eyssen M, Desloovere K, Jonkers I, de Cock P (1999) The effect of multilevel botulinum toxin type A treatment combined with short leg casting and orthotic management on the gait of CP children. Gait Posture 10: 74.
66. Desloovere K, Molenaers G, Jonkers I, van Deun S, Nijs J (2000) The effect of combined botulinum toxin injections and serial casting on gait disorders in cerebral palsy. Gait Posture 12: 57.
67. Blackmore AM, Boettcher-Hunt E, Jordan M, Chan MD (2007) A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM. Dev Med Child Neurol 49: 781-790.
68. Boyd RN, Morris ME, Graham HK (2001) Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol 8: 150-166.
69. Damiano DL, Quinlivan J, Owen BF, Shaffrey M, Abel MF (2001) Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 8: 40-49.
70. Leach J (1997) Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve Suppl 6: S194-S207.
71. Love SC, Valentine JP, Blair EM, Price CJ, Cole JH, Chauvel PJ (2001) The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia: a randomized controlled trial. Eur J Neurol 8: 50-58.
72. Ong HT, Chong HN, Yap SSP (2001) Comprehensive management of spasticity in cerebral palsy: role of physical therapy and other adjunctive treatments. Singapore Paediatr J 43: 133-136.
73. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, Becher JG (2007) Effect of multilevel botulinum toxin A and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 36(1): 30-39.
74. Smedal T, Gjelsvik B, Lygren H, Borgmann R, Waje-Andreassen U, Grønning M (2001) Botulinum toxin A-effect on spasticity. Tidsskr Nor Laegeforen 121: 3277-3280.
75. Speth LAWM, Leffers P, Janssen-Potten YJM, Vles JSH (2005) Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 47: 468-473.
76. Willoughby KL, Dodd KJ, Shields N (2009) A systematic review of the effectiveness of treadmill training for children with cerebral palsy. Disabil Rehabil 31(24): 1971-1979.
77. Hoare BJ, Imms C (2004) Upper-limb injections of botulinum toxin-A in children with cerebral palsy: a critical review of the literature and clinical implications for occupational therapists. Am J Occup Ther 58: 389-397.
78. Graham HK, Boyd R, Carlin JB, Dobson F, Lowe K, Nattrass G, Thomason P, Wolfe R, Reddihough D (2008) Does botulinum toxin A combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial. J Bone Joint Surg Am 90: 23-33.
79. Huenaerts C, Desloovere K, Molenaers G, Nijs J, Callewaert B (2004) The effects of ankle-foot-orthoses on the gait of children with cerebral palsy after treatment with botulinum toxin A: effects on temporal-spatial parameters and kinematics and kinetics of the proximal joints. Gait Posture 20: S63.
80. Fagard K, Desloovere K, Molenaers G (2009) The influence of the functional level of children with CP on the success rate for BTX-A treatment, defined by the goal attainment scale. Gait Posture.
81. van Rhijn J, Molenaers G, Ceulemans B (2005) Botulinum toxin type A in the treatment of children and adolescents with an acquired brain injury. Brain Inj 19: 331-335.
82. Chambers HG (2001) Treatment of functional limitations at the knee in ambulatory children with cerebral palsy. Eur J Neurol 8: 59-74.
83. O'Brien CF (2002) Treatment of spasticity with botulinum toxin. Clin J Pain 18: S182-S190.
84. Rutz E, Hofmann E, Brunner R (2008) Preoperative botulinum toxin to avoid poor surgical results of muscle lengthening in patients with cerebral palsy. Gait Posture 28: S2.
85. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Müller J, Poewe W (1999) Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 30: 120-124.
86. Molenaers G, Desloovere K, van Campenhout A, Pauwels P, De Cat J, Nijs J, Feys H, De Cock P (2005) Can multilevel BTX-A treatment predict the effect of SDR on gait in children with spastic diplegia? Gait Posture 22: S1-S2.
87. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ (1999) Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10: 1-9.
88. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A (1999) The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 41: 226-232.
89. Molenaers G (2008) Treatment efficacy of long-term use of botulinum toxin type A (BTXA) in children with cerebral palsy. Gait Posture 28: S1.